• LAST PRICE
    1.2900
  • TODAY'S CHANGE (%)
    Trending Down-0.0800 (-5.8394%)
  • Bid / Lots
    1.2100/ 2
  • Ask / Lots
    1.9500/ 10
  • Open / Previous Close
    1.3890 / 1.3700
  • Day Range
    Low 1.2499
    High 1.3890
  • 52 Week Range
    Low 0.6797
    High 2.3200
  • Volume
    4,290
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.37
TimeVolumePTIX
09:57 ET3001.389
09:59 ET1001.37
10:01 ET5001.38
10:03 ET21801.38
10:06 ET2001.33
12:12 ET1001.31
01:50 ET2351.2499
03:38 ET1121.31
03:59 ET2001.29
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPTIX
Protagenic Therapeutics Inc
5.7M
-1.1x
---
United StatesATXI
Avenue Therapeutics Inc
5.8M
-0.1x
---
United StatesPXMD
PaxMedica Inc
5.6M
0.0x
---
United StatesGWLL
Goldenwell Biotech Inc
5.8M
-48.0x
---
United StatesTCBP
TC BioPharm Ltd
4.7M
0.0x
---
United StatesPKTX
ProtoKinetix Inc
5.9M
-13.7x
---
As of 2024-04-21

Company Information

Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Contact Information

Headquarters
149 FIFTH AVENUE, SUITE 500NEW YORK, NY, United States 10010
Phone
212-994-8200
Fax
302-636-5454

Executives

Executive Chairman of the Board
Garo Armen
Chief Financial Officer
Alexander Arrow
Chief Operating Officer
Andrew Slee
Director, Chief Medical Officer
Robert Stein
Independent Director
Khalil Barrage

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.7M
Revenue (TTM)
$0.00
Shares Outstanding
4.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.09
EPS
$-1.15
Book Value
$0.83
P/E Ratio
-1.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.